Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

NatCan_Alvarez-Varela_2022.pdf (13.18 MB)

Document type

Article

Version

Accepted version

Publication date

2022-06-30

All rights reserved

Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/191038

Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.1038/s43018-022-00402-0

Abstract

Colorectal cancer (CRC) patient-derived organoids predict responses to chemotherapy. Here we used them to investigate relapse after treatment. Patient-derived organoids expand from highly proliferative LGR5(+) tumor cells; however, we discovered that lack of optimal growth conditions specifies a latent LGR5(+) cell state. This cell population expressed the gene MEX3A, is chemoresistant and regenerated the organoid culture after treatment. In CRC mouse models, Mex3a(+) cells contributed marginally to metastatic outgrowth; however, after chemotherapy, Mex3a(+) cells produced large cell clones that regenerated the disease. Lineage-tracing analysis showed that persister Mex3a(+) cells downregulate the WNT/stem cell gene program immediately after chemotherapy and adopt a transient state reminiscent to that of YAP(+) fetal intestinal progenitors. In contrast, Mex3a-deficient cells differentiated toward a goblet cell-like phenotype and were unable to resist chemotherapy. Our findings reveal that adaptation of cancer stem cells to suboptimal niche environments protects them from chemotherapy and identify a candidate cell of origin of relapse after treatment in CRC. Batlle and colleagues report that after chemotherapy, Mex3a(+) colorectal cancer cells represent drug-tolerant persister cells that lead to recurrence by downregulating the WNT-Lgr5(+) stem cell program and adopting a transient regenerative state.

Subject

Càncer colorectal, Quimioteràpia del càncer

Subject (English)

Colorectal cancer, Cancer chemotherapy

Citation

Collections

Articles publicats en revistes (Institut de Recerca Biomèdica (IRB Barcelona))

Citation

ALVAREZ VARELA, Adrián, et al. Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy. Nature Cancer. 2022. Vol. 3, num. 1052–1070. ISSN 2662-1347. [consulted: 17 of August of 2026]. Available at: https://hdl.handle.net/2445/191038

Export metadata

JSON - METS

Share record